Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTHFD1 | P11586 | 2/20 | 0.47 |
| ▸ | MTHFD2 | P13995 | 2/20 | 0.46 |
| ▸ | DHFR | P00374 | 2/20 | 0.43 |
| ▸ | GART | P22102 | 8/20 | 0.41 |
| ▸ | SOST | Q9BQB4 | 1/20 | 0.41 |
| ▸ | ATIC | P31939 | 3/20 | 0.41 |
| ▸ | TYMS | P04818 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3195061 | 0.84 | MTHFD1 (0.44) | MTHFD1MTHFD2DHFRGARTSOST | |
| SCHEMBL2166341 | 0.80 | MTHFD1 (0.63) | MTHFD1MTHFD2DHFRGARTSOST | |
| SCHEMBL17097094 | 0.80 | MTHFD1 (0.63) | MTHFD1MTHFD2DHFRGARTSOST | |
| SCHEMBL8406397 | 0.79 | FPGS (0.41) | MTHFD1MTHFD2DHFRGARTSOST | |
| SCHEMBL7526552 | 0.79 | GART (0.44) | MTHFD1MTHFD2DHFRGARTSOST | |
| SCHEMBL29619286 | 0.76 | TYMS (0.66) | DHFRGARTATICTYMS | |
| SCHEMBL5665622 | 0.76 | TYMS (0.66) | DHFRGARTATICTYMS | |
| SCHEMBL16085830 | 0.74 | MTHFD1 (0.55) | MTHFD1MTHFD2DHFRGARTSOST | |
| SCHEMBL5064786 | 0.74 | DHFR (0.46) | MTHFD1MTHFD2DHFRGARTSOST | |
| Folic Acid SCHEMBL8897352 | 0.71 | TYMS (0.80) | MTHFD1MTHFD2DHFRGARTSOST |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170274002-A1 | MULTIPLE FOLATE FORMULATION AND USE THEREOF | JAYMAC PHARMACEUTICALS LLC (US) | 2017-09-28 | — | — | US | disclosed |
| US-20140073598-A1 | MULTIPLE FOLATE FORMULATION AND USE THEREOF | JAYMAC PHARMACEUTICALS LLC (US) | 2014-03-13 | — | — | US | disclosed |
| EP-1891959-A1 | Contraceptive compositions for decrease risk of inborn errors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-02-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073598-A1 | MULTIPLE FOLATE FORMULATION AND USE THEREOF | MTHFD1, MTHFD2, FOLR2 | MTHFD1 1/4885MTHFD2 2/4885DHFR 6/4885 |
| US-20170274002-A1 | MULTIPLE FOLATE FORMULATION AND USE THEREOF | MTHFD1, MTHFD2, SLC19A1 | MTHFD1 1/4885MTHFD2 2/4885DHFR 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.